Search
Michigan Paid Clinical Trials
A listing of 2237 clinical trials in Michigan actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1153 - 1164 of 2237
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Michigan is currently home to 2237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Recruiting
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: 9D University Health Center, Detroit, Michigan
Conditions: Focal Onset Seizures
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Research Site, Grand Rapids, Michigan
Conditions: Gastric Cancer
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: University of Michigan Hospitals, Ann Arbor, Michigan
Conditions: Primary Generalized Tonic-Clonic Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Focal Onset Seizures
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
Recruiting
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Gender:
ALL
Ages:
Between 9 years and 25 years
Trial Updated:
06/27/2025
Locations: Wayne State University, Detroit, Michigan
Conditions: Cytomegalovirus
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Recruiting
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/27/2025
Locations: Henry Ford Cancer Institute, Detroit, Michigan
Conditions: Adult Acute Myeloid Leukemia
A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions
Recruiting
The overall goal of this research program is to address financial toxicity through the development, testing, and implementation of a multi-level communication intervention. If successful, this intervention could be a companion intervention for Cancer providers in combination with the already in testing DISCO app (Discussions of Cost App) for patients. Participants will:
* complete a baseline survey
* attend two one on one meetings, one as part of the development and the second as part of the pi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/26/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Healthy, Financial Toxicity
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Recruiting
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Cancer and Hematology Centers of Western Michigan ( Site 0015), Grand Rapids, Michigan
Conditions: Prostate Cancer, Prostatic Neoplasms
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Recruiting
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Karmanos Cancer Insitute, Detroit, Michigan
Conditions: Advanced Cancer, Breast Cancer
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Recruiting
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Head and Neck Squamous Cell Carcinoma
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Neovascular Age-related Macular Degeneration
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Recruiting
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Advanced Non-Small Cell Lung Cancer
1153 - 1164 of 2237
Clinical trials vary in time; in total a single clinical trial may take up to 15 years to complete, and some longitudinal studies ask the participant to stay in touch for follow up questions for a few years after their participation in the study is finished. Depending on the goal and the design of a clinical trial, volunteers may be asked to stay on site for a set amount of nights; this happens because the researchers might want to monitor the participant's at different hours of the day or night. Some clinical research is also setup to compensate individuals, and paid clinical trials are not uncommon.
In Michigan, the University of Michigan division of research has one of the largest clinical trial and research centers in the state, where interested volunteers can enroll in studies for healthy or non-healthy individuals. The Barbara Ann Karmanos cancer institute in Detroit, Michigan also offers clinical trials for many types of cancers for both healthy and non-healthy individuals.
Volunteers who decide to participate in a clinical trial may be compensated for their time and travel expenses during their participation in the study. The compensation will vary depending on the type of study and level of participation required from the volunteer, but paid clinical trials in Michigan are very common.
Participating in a clinical trial is always completely voluntary. This means that nobody, regardless of their condition can be forced to participate nor can they be forced to continue participating in a trial if they wish to withdraw from the study. Non-healthy individuals who decide to enroll in a clinical trial after a suggestion from their doctor or to try an experimental treatment for their condition will never be denied care if they decide to drop out of the study.
Search Clinical Trials in Michigan by Condition
See All Conditions